Compare PLAG & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAG | ALLR |
|---|---|---|
| Founded | 1986 | 2004 |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.6M | 19.3M |
| IPO Year | 2007 | 2021 |
| Metric | PLAG | ALLR |
|---|---|---|
| Price | $2.12 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 87.3K | ★ 153.4K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.56 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,040,616.00 | $320,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.47 | $0.77 |
| 52 Week High | $4.49 | $2.35 |
| Indicator | PLAG | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 57.02 | 58.13 |
| Support Level | $1.96 | $1.01 |
| Resistance Level | $2.05 | $1.43 |
| Average True Range (ATR) | 0.26 | 0.10 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 73.65 | 50.00 |
Planet Green Holdings Corp is a diversified technology and consumer products company with a presence in North America and China engaged in Chemical Products, Tea Products, and Online Advertising Services. The company operates in three segments namely to grow, produce, and distribute Cyan brick tea, black tea, and green tea in China; to research, develop, manufacture, and sell chemical products including formaldehyde, urea formaldehyde adhesive, methylal, ethanol fuel, fuel additives and clean fuel in China; and to develop and operate a demand-side platform which empowers buyers of advertising to manage and optimize their digital advertising across different real-time bidding networks in North America and China.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.